Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
McKesson
AstraZeneca
Medtronic

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR SOMATROPIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Somatropin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006143 ↗ Growth Hormone Treatment of Children With HIV-Associated Growth Failure Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A 1969-12-31 The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00006143 ↗ Growth Hormone Treatment of Children With HIV-Associated Growth Failure Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00050921 ↗ Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
NCT00079742 ↗ A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis Completed Genentech, Inc. Phase 2 2003-09-01 This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
NCT00102817 ↗ Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children Completed Novo Nordisk A/S Phase 3 2003-05-01 This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Somatropin

Condition Name

Condition Name for Somatropin
Intervention Trials
Growth Hormone Disorder 25
Growth Hormone Deficiency 24
Adult Growth Hormone Deficiency 17
Small for Gestational Age 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Somatropin
Intervention Trials
Dwarfism, Pituitary 63
Endocrine System Diseases 39
Dwarfism 22
Gonadal Dysgenesis 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Somatropin

Trials by Country

Trials by Country for Somatropin
Location Trials
United States 270
France 27
Japan 25
Germany 25
China 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Somatropin
Location Trials
New York 17
Texas 16
California 15
Massachusetts 14
Washington 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Somatropin

Clinical Trial Phase

Clinical Trial Phase for Somatropin
Clinical Trial Phase Trials
Phase 4 22
Phase 3 54
Phase 2/Phase 3 4
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Somatropin
Clinical Trial Phase Trials
Completed 109
Terminated 13
Unknown status 8
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Somatropin

Sponsor Name

Sponsor Name for Somatropin
Sponsor Trials
Novo Nordisk A/S 54
Pfizer 15
Eli Lilly and Company 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Somatropin
Sponsor Trials
Industry 144
Other 73
NIH 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.